Chinook Therapeutics, Inc. (NASDAQ:KDNY) Expected to Post Earnings of -$0.68 Per Share

Brokerages expect Chinook Therapeutics, Inc. (NASDAQ:KDNYGet Rating) to announce earnings per share (EPS) of ($0.68) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Chinook Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.74) and the highest estimate coming in at ($0.61). Chinook Therapeutics reported earnings per share of ($0.83) in the same quarter last year, which suggests a positive year over year growth rate of 18.1%. The business is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Chinook Therapeutics will report full-year earnings of ($3.04) per share for the current fiscal year, with EPS estimates ranging from ($3.30) to ($2.81). For the next fiscal year, analysts expect that the firm will post earnings of ($3.21) per share, with EPS estimates ranging from ($3.81) to ($2.98). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Chinook Therapeutics.

Chinook Therapeutics (NASDAQ:KDNYGet Rating) last issued its quarterly earnings data on Thursday, March 17th. The company reported $0.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.82. Chinook Therapeutics had a negative net margin of 199.39% and a negative return on equity of 26.45%.

Separately, Zacks Investment Research cut shares of Chinook Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 22nd.

In related news, COO Tom Frohlich sold 3,735 shares of the business’s stock in a transaction dated Friday, February 11th. The stock was sold at an average price of $12.74, for a total value of $47,583.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew James King sold 2,500 shares of the company’s stock in a transaction on Thursday, February 10th. The stock was sold at an average price of $13.31, for a total transaction of $33,275.00. The disclosure for this sale can be found here. In the last three months, insiders sold 14,630 shares of company stock valued at $201,561. Insiders own 29.75% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Morgan Stanley boosted its position in shares of Chinook Therapeutics by 5,323.7% during the second quarter. Morgan Stanley now owns 67,145 shares of the company’s stock valued at $948,000 after buying an additional 65,907 shares during the last quarter. Royal Bank of Canada lifted its stake in Chinook Therapeutics by 193.7% during the 2nd quarter. Royal Bank of Canada now owns 2,182 shares of the company’s stock valued at $30,000 after acquiring an additional 1,439 shares in the last quarter. Invesco Ltd. bought a new position in Chinook Therapeutics during the 2nd quarter valued at $148,000. SG Americas Securities LLC purchased a new position in Chinook Therapeutics during the 3rd quarter worth $289,000. Finally, Candriam Luxembourg S.C.A. grew its stake in shares of Chinook Therapeutics by 3.1% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 902,537 shares of the company’s stock worth $11,516,000 after acquiring an additional 27,413 shares in the last quarter. Institutional investors own 72.25% of the company’s stock.

Chinook Therapeutics stock traded up $0.07 during trading hours on Wednesday, hitting $15.65. The stock had a trading volume of 214,763 shares, compared to its average volume of 339,849. The business’s 50 day simple moving average is $14.24 and its 200-day simple moving average is $14.28. Chinook Therapeutics has a one year low of $10.48 and a one year high of $19.85. The stock has a market cap of $859.98 million, a price-to-earnings ratio of -6.52 and a beta of 0.05.

About Chinook Therapeutics (Get Rating)

Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

See Also

Get a free copy of the Zacks research report on Chinook Therapeutics (KDNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chinook Therapeutics (NASDAQ:KDNY)

Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.